More recently, distinct cancer-associated mutations in EZH2 have been reported, including gain-of-function mutations in lymphoid malignancies and loss-of-function mutations in myeloid malignancies where they are also associated with a poor prognosis (42). This evidence concerns the gene EZH2 and myeloid neoplasm.